Therapies for acute renal failure
AssigneeStryker Corporation
InventorsCharles M. Cohen, Kuber T. Sampath, Slobodan Vukicevic
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins.
Claims19
A method for treating a mammal in, or at risk of, acute renal failure comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent.
A method for treating a mammal to delay the need for, or reduce the frequency of, dialysis treatments of said mammal, the method comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent.
3-4. (canceled)
7-18. (canceled)
(canceled)
26-29. (canceled)
32-36. (canceled)
38-52. (canceled)
Dependencies are inferred from the claim text.